News articles about Aevi Genomic Medicine (NASDAQ:GNMX) have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aevi Genomic Medicine earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 44.8667483426979 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Separately, Jefferies Group reissued a “hold” rating and set a $1.50 price target on shares of Aevi Genomic Medicine in a research report on Thursday, September 28th.
Aevi Genomic Medicine (GNMX) traded down $0.08 during trading hours on Tuesday, reaching $1.26. The company had a trading volume of 95,400 shares, compared to its average volume of 171,940. The firm has a market capitalization of $79.50, a price-to-earnings ratio of -1.31 and a beta of 0.40. Aevi Genomic Medicine has a 52-week low of $0.98 and a 52-week high of $6.18.
In other news, CEO Michael F. Cola bought 119,047 shares of the company’s stock in a transaction on Tuesday, October 17th. The shares were bought at an average cost of $1.26 per share, with a total value of $149,999.22. Following the transaction, the chief executive officer now directly owns 218,483 shares in the company, valued at approximately $275,288.58. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Garry Arthur Neil bought 75,000 shares of the company’s stock in a transaction on Tuesday, October 17th. The stock was purchased at an average cost of $1.26 per share, for a total transaction of $94,500.00. Following the completion of the transaction, the insider now owns 114,774 shares in the company, valued at $144,615.24. The disclosure for this purchase can be found here. Insiders have purchased 615,079 shares of company stock worth $775,000 over the last three months. 15.20% of the stock is owned by insiders.
Aevi Genomic Medicine Company Profile
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease.
Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.